Researchers at one of the nation’s top cancer institutes are betting on a combination of radiation and immunotherapy in the continued pursuit of better treatments for malignant mesothelioma. Memorial Sloan Kettering in New York is now recruiting relapsed mesothelioma patients into a safety and efficacy study of stereotactic body radiation therapy (SBRT) and the immunotherapy drug avelumab. The new trial is based on the idea … Continue reading New Mesothelioma Treatment Combines Immunotherapy and Targeted Radiation
A new Japanese study is calling into question the value of a common prognostic test for people with malignant pleural mesothelioma. The test is called the neutrophil-to-lymphocyte ratio or NLR and it is used in many types of diseases, including mesothelioma, as a marker for inflammation. But in a new report published in the journal In Vivo, researchers with the Hyogo Prefectural Amagasaki General Medical … Continue reading Blood Test May Not Predict Mesothelioma Survival as Well as Hoped
A new stem cell vaccine that has proven effective against malignant mesothelioma and several other cancers in mice might offer a promising new way to treat the asbestos cancer. Although rare, malignant mesothelioma is one of the most treatment-resistant malignancies. Even with aggressive therapies, most people diagnosed with mesothelioma do not survive longer than about 18 months. But research conducted at Stanford University and published in … Continue reading Could Stem Cell Vaccine Lead to Mesothelioma Cure?
A new study is casting some doubt on the value of a protein called PD-L1 as a way to select mesothelioma patients for targeted immunotherapy. Several of the most promising new treatments for malignant mesothelioma, including pembrolizumab (Keytruda) and avelumab (Avastin), are designed to inhibit PD-L1, a protein cells used to evade detection by the immune system. PD-L1 inhibitors like Keytruda have become an important … Continue reading Study Highlights Challenge of Selecting Patients for Mesothelioma Immunotherapy
Immunotherapy is emerging as one of the most promising new treatment approaches for a wide range of cancers, including malignant pleural mesothelioma, the treatment-resistant lung-related cancer caused by asbestos exposure. Every year, more than 2,500 Americans are diagnosed with pleural mesothelioma. Most will die of the illness within 18 months, even with the most advanced chemotherapeutic, radiotherapeutic, and surgical treatments. But immunotherapy, which recruits the … Continue reading Immunotherapy for Mesothelioma: Who Are the Best Candidates?
France has a new standard of care for people with unresectable malignant pleural mesothelioma. Along with the chemotherapy drugs cisplatin and pemetrexed (Alimta), French doctors are now regularly also using bevacizumab (Avastin) to boost the effectiveness of mesothelioma chemotherapy. The addition of Avastin to standard mesothelioma care came after the 2016 French-led mesothelioma avastin cisplatin pemetrexed study (MAPS) showed that the VEGF inhibitor improved mesothelioma … Continue reading Three-Drug Combo is New Standard of Care for Pleural Mesothelioma in France
The ratio of neutrophils to lymphocytes – a way of measuring inflammation in the body of people with malignant pleural mesothelioma – may help doctors predict how well they will respond to treatment. That is the conclusion of mesothelioma researchers at China’s Sichuan University. In a new article in the journal Oncotarget, the team observed that NLR has been associated with survival in other types … Continue reading Inflammation Marker May Predict Mesothelioma Prognosis
Immune system cells may be some of the best predictors of mesothelioma outcomes, according to a group of British scientists. A new article in the British Journal of Cancer has found a close association between outcomes in people with different subtypes of malignant mesothelioma and the levels of different types of immune system cells in their bodies. Measuring Immune Response To create the experiment, researchers … Continue reading Using Immune Cells to Predict Mesothelioma Outcomes
New evidence suggests that mesothelioma patients whose tumors express two particular proteins do not live as long as other mesothelioma patients. An international team of scientists including mesothelioma researchers at the National Cancer Institute say ALCAM (also called CD166) and PD-L1 (CD274) are both associated with “significantly decreased” survival in pleural mesothelioma. Understanding ALCAM and PD-L1 ALCAM is a type I transmembrane protein that regulates … Continue reading These Proteins Appear to Shorten Mesothelioma Survival
A large international clinical trial of the immunotherapy drug tremelimumab as a second- or third-line treatment option for malignant mesothelioma has produced some disappointing news. Drug maker AstraZeneca has just released an update on the ongoing DETERMINE trial which suggests that the survival rates are roughly the same for previously-treated mesothelioma patients whether they later received treatment with tremelimumab or a placebo. What is Tremelimumab? … Continue reading Second-Line Immunotherapy Treatment Fails to Improve Mesothelioma Survival